Ionis Pharmaceuticals, Inc. (IONS)
26.58
-0.64
(-2.35%)
USD |
NASDAQ |
Nov 20, 16:00
26.60
+0.02
(+0.08%)
After-Hours: 20:00
Ionis Pharmaceuticals Research and Development Expense (TTM) : 921.08M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 921.08M |
| June 30, 2026 | 923.08M |
| March 31, 2026 | 923.53M |
| December 31, 2025 | 914.12M |
| September 30, 2025 | 879.75M |
| June 30, 2025 | 882.38M |
| March 31, 2025 | 887.58M |
| December 31, 2024 | 901.04M |
| September 30, 2024 | 913.04M |
| June 30, 2024 | 908.61M |
| March 31, 2024 | 916.47M |
| December 31, 2023 | 900.07M |
| September 30, 2023 | 951.07M |
| June 30, 2023 | 918.73M |
| March 31, 2023 | 869.56M |
| December 31, 2022 | 832.87M |
| September 30, 2022 | 703.87M |
| June 30, 2022 | 705.65M |
| March 31, 2022 | 664.20M |
| December 31, 2021 | 642.88M |
| September 30, 2021 | 634.88M |
| June 30, 2021 | 575.19M |
| March 31, 2021 | 558.15M |
| December 31, 2020 | 535.30M |
| September 30, 2020 | 512.91M |
| Date | Value |
|---|---|
| June 30, 2020 | 492.06M |
| March 31, 2020 | 475.82M |
| December 31, 2019 | 465.17M |
| September 30, 2019 | 429.89M |
| June 30, 2019 | 420.79M |
| March 31, 2019 | 416.49M |
| December 31, 2018 | 414.16M |
| September 30, 2018 | 429.05M |
| June 30, 2018 | 414.07M |
| March 31, 2018 | 395.79M |
| December 31, 2017 | 374.40M |
| September 30, 2017 | 347.27M |
| June 30, 2017 | 350.97M |
| March 31, 2017 | 344.94M |
| December 31, 2016 | 342.87M |
| September 30, 2016 | 341.83M |
| June 30, 2016 | 345.94M |
| March 31, 2016 | 335.98M |
| December 31, 2015 | 319.38M |
| September 30, 2015 | 286.75M |
| June 30, 2015 | 259.31M |
| March 31, 2015 | 250.54M |
| December 31, 2014 | 239.51M |
| September 30, 2014 | 228.95M |
| June 30, 2014 | 213.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.559B |
| Arrowhead Pharmaceuticals, Inc. | 929.60M |
| BridgeBio Pharma, Inc. | 536.01M |
| Biogen, Inc. | 1.872B |
| TG Therapeutics, Inc. | 236.22M |